Overview

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Zoledronate may delay or prevent bone marrow metastases in patients with breast cancer. PURPOSE: This phase II trial is studying how well zoledronate works in treating bone marrow micrometastases in women with stage I, stage II, or stage III breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Cancer Institute (NCI)
Novartis
Treatments:
Diphosphonates
Zoledronic Acid